leisure time -WSS

leisure time

author：entertainment 2025-10-02 21:05:30 - browse：22

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： How one medical school became remarkably diverse
Next article： JPM: CVS says Medicare Advantage patients are impacting profits

focus

WSS

JPM: CVS says Medicare Advantage patients are impacting profits

Goldman Sachs launches $650M fund for life science investments

Antibiotic resistance and the global rise in human conflict

Why psychiatrists like me stop taking insurance

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

UCB departs biotech trade group BIO

Wikipedia

leisure time

entertainment

Medicare details structure of new drug price negotiation program

Hospital price transparency does save money, advocate argues

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Solve the antibiotic resistance crisis with preventive drugs

Medicare details structure of new drug price negotiation program

UnitedHealth’s board chair also owns a personal investment firm

As demand for Covid shots wanes, Moderna seeks its next success

Why psychiatrists like me stop taking insurance

Apple is now the first public company to be valued at $3 trillion

STAT Summit: Biotech founders on deal

focus

Goldman Sachs launches $650M fund for life science investments

2023 STAT Wunderkinds: get to know the winners

CEOs share strategies for surviving biotech slump

STAT Summit: Biotech founders on deal

Lawmakers consider Medicare pay reforms for doctors

UnitedHealth’s board chair also owns a personal investment firm

entertainment

focus

hotspot

leisure time